Clinical and pharmacological assessment of the combination of valsartan and amlodipine for the treatment of arterial hypertension against the background of comorbidity

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Arterial hypertension (AH) is widespread among the adult population and is one of the main and independent risk factors for the development of cardiovascular, cerebrovascular and renal diseases. Taking into account the high prevalence of comorbid pathology and the associated high cardiovascular risk, the choice of antihypertensive drugs (AHDs) is particularly important. The current dominant strategy for the treatment of AH is the use of fixed combinations of antihypertensive drugs, which increase patient adherence to treatment and ultimately increase the frequency of achieving the target blood pressure (BP) level. Valsartan and amlodipine are drugs with proven effectiveness and safety and can act as first-line drugs for the treatment of AH in patients with comorbid pathology. The use of the fixed combination of valsartan/amlodipine is associated with a more pronounced absolute reduction in blood pressure and fewer cases of antihypertensive discontinuation due to side effects and non-compliance with treatment compared with the use of individual drugs in monotherapy. The high antihypertensive effectiveness of the fixed combination of valsartan/amlodipine has been shown in patients with broncho-obstructive diseases and smokers. Valsartan in combination with amlodipine has a positive effect on the course of diabetic nephropathy, which allows us to recommend this combination as the first line of antihypertensive therapy for patients with this pathology. The fixed combination of valsartan/amlodipine reduces the risks of cardiovascular complications and improves the long-term prognosis of hypertensive patients.

全文:

受限制的访问

作者简介

Olga Mubarakshina

Voronezh State Medical University n.a. N.N. Burdenko

编辑信件的主要联系方式.
Email: mubarakshina@mail.ru
ORCID iD: 0000-0001-6799-6322

Cand. Sci. (Med.), Associate Professor at the Department of Clinical Pharmacology

俄罗斯联邦, Voronezh

M. Somova

Voronezh State Medical University n.a. N.N. Burdenko

Email: mubarakshina@mail.ru
ORCID iD: 0000-0002-6511-4098
俄罗斯联邦, Voronezh

G. Batishcheva

Voronezh State Medical University n.a. N.N. Burdenko

Email: mubarakshina@mail.ru
ORCID iD: 0000-0003-4771-7466
俄罗斯联邦, Voronezh

O. Zhdanova

Voronezh State Medical University n.a. N.N. Burdenko

Email: mubarakshina@mail.ru
ORCID iD: 0000-0002-3917-0395
俄罗斯联邦, Voronezh

E. Kurbatova

Voronezh City Clinical Clinic No. 7

Email: mubarakshina@mail.ru
ORCID iD: 0009-0000-6522-867X
俄罗斯联邦, Voronezh

参考

  1. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA): Erratum. J Hypertens. 2024;42(1):194. doi: 10.1097/HJH.0000000000003621.
  2. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. [Kobalava Zh.D., Konradi A.O., Nedogoda S.V. and others. Arterial hypertension in adults. Clinical guidelines 2020. Rus J Cardiol.=Rossiiskii kardiologicheskii zhurnal. 2020;25(3):3786. (In Russ.)]. doi: 10.15829/1560-4071-2020-3-3786.
  3. Algharally E.A.-H., Kreutz R. Classes of antihypertensive drugs. European Society of Hypertension Guidelines on Hypertension: CRC Press; 2019. Р. 325–35.
  4. Kreutz R., Algarabelli E.A.-H. Antihypertensive drugs. In: Offermanns S, Rosenthal W, editors. Encyclopedia of molecular pharmacology. Cham: Springer International Publishing House; 2021. Р. 165–74.
  5. Rea F., et al. Initial Antihypertensive Treatment Strategies and Therapeutic Inertia: Evidence From a Large Population-Based Cohort. Hypertension. 2018;72(4):846–53.
  6. Savare L., et al. Use of initial and subsequent antihypertensive combination treatment in the last decade: analysis of a large Italian database. J Hypertens. 2022;40(9):1768–75.
  7. Романенко В.В., Романенко З.В. Ингибиторы АПФ – препараты первой линии в лечении сердечно-сосудистых заболеваний. Международные обзоры: клиническая практика и здоровье. 2014;3(9). [Romanenko V.V., Romanenko Z.V. ACE inhibitors are first-line drugs in the treatment of cardiovascular diseases. Mezhdunarodnye obzory: klinicheskaya praktika i zdorov’e. 2014;3(9). (In Russ.)].
  8. Savarese G., et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am College Cardiol. 2013;61(2):131–42.
  9. Burnett H., et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation: Heart Failure. 2017;10(1):e003529.
  10. Van Vark L.C., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33(16):2088–97.
  11. Messerli F.H., et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am College Cardiol. 2018;71(13): 1474–82.
  12. Gallo G., Volpe M., Rubattu S. Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations. Vasc Health Risk Management. 2022. Р. 507–15.
  13. Reboldi G., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282–89.
  14. Corrao G., et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819–24.
  15. Bhandari S., et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387(22):2021–32.
  16. Sarafidis P.A., et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol: CJASN. 2012;7(8):1234.
  17. Moen M.F., et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol: CJASN. 2009;4(6):1121.
  18. Epstein M., et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(Suppl. 11): S212–20.
  19. Yildirim T., et al. Major barriers against renin–angiotensin–aldosterone system blocker use in chronic kidney disease stages 3–5 in clinical practice: a safety concern? Renal Failure. 2012;34(9):1095–99.
  20. Fu E.L., et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J Am Soc Nephrol: JASN. 2021;32(2):424.
  21. Yang A., et al. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study. EClinicalMedicine. 2023;55.
  22. Sarafidis P.A., Khosla N., Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12–26.
  23. Ott C., Schmieder R.E. Diagnosis and treatment of arterial hypertension 2021. Kidney Int. 2022;101(1):36–46.
  24. Chandy D., Aronov W.S., Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integrat. Blood Pressure Control. 2013;6:101–9.
  25. Mancini G.B.J., Etminan M., Zhang B., et al. Reduction of morbidity and mortality statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. JACC. 2006;47 (12):2554–60.
  26. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs–overview and meta-analyses. J Hypertens. 2015;33(7):1321–41.
  27. Wang Y.C., et al. Risks of adverse events following coprescription of statins and calcium channel blockers: a nationwide population-based study. Medicine. 2016;95(2).
  28. Xu Y., et al. Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation. J Am Heart Associat. 2022;11(14):e025723.
  29. Pham P., et al. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA network open. 2020;3(4):e203593.
  30. Wei J., et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Network Open. 2020;3(2):e1921618–618.
  31. Psaty B.M., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.
  32. Chalmers J., et al. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. J Hypertens. 2023;41(3):508.
  33. Roush G.C., et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–46.
  34. Olde Engberink R.H.G., et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033–40.
  35. Brown M.J., et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diab Endocrinol. 2016;4(2):136–47.
  36. Zillich A.J., et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24.
  37. Карпов Ю.А., Мелехов А.В. Валсартан – ключ к решению вопросов профилактики сердечно-сосудистых заболеваний. Атмосфера. Новости кардиологии. 2018;1. [Karpov Yu.A., Melekhov A.V. Valsartan is the key to solving the problems of preventing cardiovascular diseases. Atmosfera. Novosti kardiologii. 2018;1. (In Russ.)].
  38. Леонова М.В. Валсартан: от клинической фармакологии к гипотензивной эффективности и фармакоэкономическим преимуществам в лечении артериальной гипертонии. Справочник поликлинического врача. 2013;9:11–6. [Leonova M.V. Valsartan: from clinical pharmacology to antihypertensive efficacy and pharmacoeconomic advantages in the treatment of arterial hypertension. Spravochnik poliklinicheskogo vracha. 2013;9:11–6. (In Russ.)].
  39. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract. 2009;63(5):766–75.
  40. Ogihara T., Saruta T., Rakugi H., et al. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56(2):196–202.
  41. Преображенский Д.В., Носенко Н.С., Некрасова Н.И. и др. Антагонист кальция третьего поколения амлодипин: особенности клинической фармакологии и спектр терапевтического применения. Русский медицинский журнал. 2011;14:884. Preobrazhensky D.V., Nosenko N.S., Nekrasova N.I. et al. Third generation calcium antagonist amlodipine: features of clinical pharmacology and range of therapeutic use. Russkii meditsinskii zhurnal. 2011;14:884. (In Russ.)].
  42. Леонова М.В. Клиническая фармакология и клиническая эффективность амлодипина. Данные доказательной медицины. Медицинский совет. 2014;(12):25–32. Leonova M.V. Clinical pharmacology and clinical efficacy of amlodipine. Data from evidence-based medicine. Meditsinskii sovet. 2014;(12):25–32. (In Russ.)]. doi: 10.21518/2079-701X-2014-12-25-32.
  43. Levine C.B., Fahrbach K.R., Frame D., et al. Effect of amlodipine on systolic blood pressure. Clin Ther. 2003;25:35–57.
  44. Духанин А.С., Подзолков В.И., Тарзиманова А.И. Амлодипин в лечении артериальной гипертензии: всегда ли генерик эквивалентен оригинальному препарату? Русский медицинский журнал. Кардиология. 2010;18(9):556–59. Dukhanin A.S., Podzolkov V.I., Tarzimanova A.I. Amlodipine in the treatment of arterial hypertension: is the generic always equivalent to the original drug? Russkii meditsinskii zhurnal. Kardiologiya. 2010;18(9):556–59. (In Russ.)].
  45. Xie M., Tang T., Liang H. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. Clin Cardiol. 2023;46(8):886–98. doi: 10.1002/clc.24082.
  46. Wilke Th., Weisser B., Predel H.-G., et al. Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: Integr. Blood Press. Control. 2022;15:11–21. doi: 10.2147/IBPC.S336324.
  47. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet. 2004;363(9426):2022–31.
  48. Чазова И.Е., Карпов Ю.А., Вигдорчик А.В. Эффективность и безопасность комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: первые результаты российского наблюдательного исследования ЭКСТРА. Системные гипертензии. 2010;2:18–26. [Chazova I.E., Karpov Yu.A., Vigdorchik A.V. Efficacy and safety of the combination of amlodipine and valsartan in the treatment of arterial hypertension in real clinical practice: first results of the Russian observational study EXTRA. Sistemnye gipertenzii. 2010;2:18–26. (In Russ.)].
  49. Карпов Ю.А., Чазова И.Е., Вигдорчик А.В., Зазулина А.Ю. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Кардиологический вестник. 2010;5:39–46. [Karpov Yu.A., Chazova I.E., Vigdorchik A.V., Zazulina A.Yu. Efficacy and safety of a fixed combination of amlodipine and valsartan in the treatment of arterial hypertension in real clinical practice: results of the Russian observational study EXTRA-2. Kardiologicheskii vestnik. 2010;5:39–46. (In Russ.)].
  50. Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Фиксированная комбинация валсартана и амлодипина в лечении резистентной и неконтролируемой артериальной гипертонии (Российский регистр неконтролируемой и резистентной артериальной гипертензии РЕГАТА-ЭКСТРА «Резистентная Гипертония АрТериальная – ЭКСфорж в Терапии Резистентной Артериальной гипертензии»). Системные гипертензии. 2011;8(1):5–9. [Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Fixed combination of valsartan and amlodipine in the treatment of resistant and uncontrolled arterial hypertension (Russian register of uncontrolled and resistant arterial hypertension REGATA-EXTRA “Resistant Hypertension Arterial - EXforge in the Therapy of Resistant Arterial Hypertension”). Sistemnye gipertenzii. 2011;8(1):5–9. (In Russ.)].
  51. Бубнова М.А., Крючкова О.Н., Ицкова Е.А. и др. Эффективность применения комбинаций периндоприл/амлодипин и валсартан/амлодипин у пациентов с сочетанием артериальной гипертензии и хронической обструктивной болезни легких. Южно-Российский журнал терапевтической практики. 2022;3(1):42–9. [Bubnova M.A., Kryuchkova O.N., Itskova E.A., et al. The effectiveness of the use of combinations of perindopril/amlodipine and valsartan/amlodipine in patients with a combination of arterial hypertension and chronic obstructive pulmonary disease. Yuzhno-Rossiiskii zhurnal terapevticheskoi praktiki. 2022;3(1):42–9. (In Russ.)]. doi: 10.21886/2712-8156-20223-1-42-49.
  52. Su F., Xia Q. Effects of Valsartan and Amlodipine Tablets Combined with β-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. Altern Ther Health Med. 2023;29(5):126–31.
  53. Zhang W., Song Y., Xu J. Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis. Medicine (Baltimore). 2017;96(26):e7172. doi: 10.1097/MD.0000000000007172.
  54. Malesker M.A., Hilleman D.E. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care. 2010;19(7):36–42.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2024